Femasys Announces Strategic Partnership with OR Consulting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Should l Buy FEMY?
Femasys announced a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland. The agreement includes FemBloc Permanent Birth Control, FemaSeed Intratubal Insemination, and additional Femasys fertility and women's diagnostic health products. Together with the Company's recent market entry in Spain and the ongoing commercial launch in France, this partnership represents continued execution of Femasys' European expansion strategy and broadens access to its innovative technologies through experienced regional partners.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FEMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FEMY
Wall Street analysts forecast FEMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FEMY is 4.75 USD with a low forecast of 3.00 USD and a high forecast of 6.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.485
Low
3.00
Averages
4.75
High
6.50
Current: 0.485
Low
3.00
Averages
4.75
High
6.50
About FEMY
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Femasys Partners with OR Consulting for Swiss Market Launch
- Strategic Partnership: Femasys has announced a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland, including FemBloc permanent birth control and FemaSeed intratubal insemination, further advancing Femasys' European expansion strategy.
- Market Expansion Plan: This partnership signifies Femasys' continued market entry following successful launches in Spain and France, demonstrating the company's commitment to building a robust commercial platform across multiple countries.
- Product Innovation Advantage: FemBloc, the first non-surgical permanent birth control method, received full regulatory approval in Europe in 2025, and is expected to meet the growing demand in women's health with its effective and safe profile.
- Market Potential: Switzerland is recognized as a key market for women's health innovation, and the collaboration between Femasys and OR Consulting aims to enhance patient options through close cooperation with physicians, facilitating effective navigation in complex markets.
See More
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
- FDA Orphan Drug Designation: Atossa Therapeutics (ATOS) announced that its (Z)-endoxifen received Orphan Drug Designation from the FDA, leading to a 12.98% stock increase to $0.69, marking a significant milestone in the treatment of Duchenne muscular dystrophy and expected to drive future R&D progress.
- Clinical Trial Progress: ImmunityBio (IBRX) reported that over 85% of the study population has been enrolled in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer, with stock rising 9.43% to $6.04, and full enrollment anticipated by Q2 2026, enhancing market confidence.
- NASDAQ Compliance Extension: Femasys (FEMY) received NASDAQ approval for a 180-day extension to meet the minimum $1.00 bid price requirement, with stock climbing 10.68% to $0.72, providing the company until July 13, 2026, to regain compliance, alleviating investor concerns.
- Successful Financing: Foghorn Therapeutics (FHTX) closed a $50 million registered direct financing at a 30% premium, resulting in a 4.02% stock increase to $6.26, demonstrating market confidence and support for its future development.
See More
Femasys (FEMY) Receives Nasdaq Approval for 180-Day Compliance Extension Until July 2026
- Compliance Extension: Femasys has received Nasdaq approval for a 180-day extension until July 13, 2026, to meet the minimum closing bid price requirement of $1.00 per share, ensuring the company's continued listing status on the capital market.
- Stable Listing Status: The extension notice does not immediately affect Femasys's listing status on Nasdaq, indicating the company's resilience and operational capability amid market challenges.
- Market Reaction: FEMY shares fell 0.81% in premarket trading to $0.5809, reflecting cautious investor sentiment regarding the company's compliance progress, which may impact future financing and market confidence.
- Financing Context: Recently, Femasys secured $12 million in financing and received FDA approval for the final FemBloc trial, demonstrating positive advancements in product development and fundraising despite compliance pressures.
See More
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
- Alumis Clinical Progress: Alumis Inc. announced it will report topline data from its Phase 3 ONWARD clinical trial for moderate-to-severe plaque psoriasis on January 6, 2026, leading to a 17.33% stock surge, reflecting strong investor optimism ahead of the results.
- Genelux Trial Results: Genelux Corp. saw a 10.92% increase in share price following interim results from two ongoing trials, indicating that its Olvi-Vec may effectively resensitize tumors in small cell and non-small cell lung cancer patients, boosting market confidence in its product.
- Bright Minds Conference Announcement: Bright Minds Biosciences Inc. will host a conference call on January 6, 2026, to report results from its Phase 2 trial for drug-resistant absence seizures, with an 8.42% stock increase reflecting market anticipation for its findings.
- Alpha Tau FDA Submission: Alpha Tau Medical Ltd. submitted the first module of its pre-market approval application for Alpha DaRT to treat recurrent cutaneous squamous cell carcinoma, resulting in a 5.36% stock rise, as this modular approach may expedite the approval process and enhance market confidence.
See More
Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025
- Significant Revenue Growth: Multi Ways Holdings reported net revenue of $26.44 million for the first half of 2025, representing an impressive 87.65% increase from $14.09 million in the same period last year, indicating strong market demand and business expansion capabilities.
- Surge in Stock Price: Following the positive earnings report, the company's shares jumped 59.6% to $0.40 in pre-market trading, reflecting investor confidence in the company's future growth potential.
- Positive Market Reaction: The release of the financial results has significantly increased market attention on Multi Ways Holdings, which is expected to attract more investors to its future developments and strategic plans.
- Strategic Growth Outlook: The robust financial performance not only solidifies the company's position in the industry but also provides ample funding for future expansion and investments, potentially driving further increases in market share.
See More
Weekly Update: CYTK Receives Initial FDA Approval, INSM Concludes Rhinosinusitis Research, XOMA Purchases GBIO
FDA Approvals: Several biotech companies received FDA approvals for new therapies, including GSK's Exdensur for severe asthma, Johnson & Johnson's RYBREVANT FASPRO for non-small cell lung cancer, and Amphastar's Teriparatide Injection for osteoporosis, among others.
Acquisitions: XOMA Royalty and Swedish Orphan Biovitrum AB made significant acquisitions to enhance their portfolios, with XOMA acquiring Generation Bio and SOBI set to acquire Arthrosi Therapeutics for up to $1.5 billion.
Clinical Trial Outcomes: Insmed and Argenx faced setbacks as they discontinued clinical trials due to disappointing results, while other companies like Processa and DBV Technologies reported positive outcomes in their respective trials.
New Drug Developments: Athira secured exclusive rights to the breast cancer drug Lasofoxifene, and Takeda's Zasocitinib met primary endpoints in a Phase 3 study for plaque psoriasis, showcasing ongoing advancements in drug development within the biotech sector.
See More
Femasys Partners with OR Consulting for Swiss Market Launch
- Strategic Partnership: Femasys has announced a new strategic distribution partnership with OR Consulting to support the commercial launch of its product portfolio in Switzerland, including FemBloc permanent birth control and FemaSeed intratubal insemination, further advancing Femasys' European expansion strategy.
- Market Expansion Plan: This partnership signifies Femasys' continued market entry following successful launches in Spain and France, demonstrating the company's commitment to building a robust commercial platform across multiple countries.
- Product Innovation Advantage: FemBloc, the first non-surgical permanent birth control method, received full regulatory approval in Europe in 2025, and is expected to meet the growing demand in women's health with its effective and safe profile.
- Market Potential: Switzerland is recognized as a key market for women's health innovation, and the collaboration between Femasys and OR Consulting aims to enhance patient options through close cooperation with physicians, facilitating effective navigation in complex markets.
See More
Atossa Therapeutics Receives FDA Orphan Drug Designation, Stock Rises Nearly 13%
- FDA Orphan Drug Designation: Atossa Therapeutics (ATOS) announced that its (Z)-endoxifen received Orphan Drug Designation from the FDA, leading to a 12.98% stock increase to $0.69, marking a significant milestone in the treatment of Duchenne muscular dystrophy and expected to drive future R&D progress.
- Clinical Trial Progress: ImmunityBio (IBRX) reported that over 85% of the study population has been enrolled in its registrational trial QUILT-2.005 for BCG-naïve non-muscle-invasive bladder cancer, with stock rising 9.43% to $6.04, and full enrollment anticipated by Q2 2026, enhancing market confidence.
- NASDAQ Compliance Extension: Femasys (FEMY) received NASDAQ approval for a 180-day extension to meet the minimum $1.00 bid price requirement, with stock climbing 10.68% to $0.72, providing the company until July 13, 2026, to regain compliance, alleviating investor concerns.
- Successful Financing: Foghorn Therapeutics (FHTX) closed a $50 million registered direct financing at a 30% premium, resulting in a 4.02% stock increase to $6.26, demonstrating market confidence and support for its future development.
See More
Femasys (FEMY) Receives Nasdaq Approval for 180-Day Compliance Extension Until July 2026
- Compliance Extension: Femasys has received Nasdaq approval for a 180-day extension until July 13, 2026, to meet the minimum closing bid price requirement of $1.00 per share, ensuring the company's continued listing status on the capital market.
- Stable Listing Status: The extension notice does not immediately affect Femasys's listing status on Nasdaq, indicating the company's resilience and operational capability amid market challenges.
- Market Reaction: FEMY shares fell 0.81% in premarket trading to $0.5809, reflecting cautious investor sentiment regarding the company's compliance progress, which may impact future financing and market confidence.
- Financing Context: Recently, Femasys secured $12 million in financing and received FDA approval for the final FemBloc trial, demonstrating positive advancements in product development and fundraising despite compliance pressures.
See More
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
- Alumis Clinical Progress: Alumis Inc. announced it will report topline data from its Phase 3 ONWARD clinical trial for moderate-to-severe plaque psoriasis on January 6, 2026, leading to a 17.33% stock surge, reflecting strong investor optimism ahead of the results.
- Genelux Trial Results: Genelux Corp. saw a 10.92% increase in share price following interim results from two ongoing trials, indicating that its Olvi-Vec may effectively resensitize tumors in small cell and non-small cell lung cancer patients, boosting market confidence in its product.
- Bright Minds Conference Announcement: Bright Minds Biosciences Inc. will host a conference call on January 6, 2026, to report results from its Phase 2 trial for drug-resistant absence seizures, with an 8.42% stock increase reflecting market anticipation for its findings.
- Alpha Tau FDA Submission: Alpha Tau Medical Ltd. submitted the first module of its pre-market approval application for Alpha DaRT to treat recurrent cutaneous squamous cell carcinoma, resulting in a 5.36% stock rise, as this modular approach may expedite the approval process and enhance market confidence.
See More
Multi Ways Holdings Reports 87.65% Revenue Growth to $26.44 Million in H1 2025
- Significant Revenue Growth: Multi Ways Holdings reported net revenue of $26.44 million for the first half of 2025, representing an impressive 87.65% increase from $14.09 million in the same period last year, indicating strong market demand and business expansion capabilities.
- Surge in Stock Price: Following the positive earnings report, the company's shares jumped 59.6% to $0.40 in pre-market trading, reflecting investor confidence in the company's future growth potential.
- Positive Market Reaction: The release of the financial results has significantly increased market attention on Multi Ways Holdings, which is expected to attract more investors to its future developments and strategic plans.
- Strategic Growth Outlook: The robust financial performance not only solidifies the company's position in the industry but also provides ample funding for future expansion and investments, potentially driving further increases in market share.
See More
Weekly Update: CYTK Receives Initial FDA Approval, INSM Concludes Rhinosinusitis Research, XOMA Purchases GBIO
FDA Approvals: Several biotech companies received FDA approvals for new therapies, including GSK's Exdensur for severe asthma, Johnson & Johnson's RYBREVANT FASPRO for non-small cell lung cancer, and Amphastar's Teriparatide Injection for osteoporosis, among others.
Acquisitions: XOMA Royalty and Swedish Orphan Biovitrum AB made significant acquisitions to enhance their portfolios, with XOMA acquiring Generation Bio and SOBI set to acquire Arthrosi Therapeutics for up to $1.5 billion.
Clinical Trial Outcomes: Insmed and Argenx faced setbacks as they discontinued clinical trials due to disappointing results, while other companies like Processa and DBV Technologies reported positive outcomes in their respective trials.
New Drug Developments: Athira secured exclusive rights to the breast cancer drug Lasofoxifene, and Takeda's Zasocitinib met primary endpoints in a Phase 3 study for plaque psoriasis, showcasing ongoing advancements in drug development within the biotech sector.
See More
